<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">717853</article-id><article-id pub-id-type="doi">10.26442/20751753.2026.8.203827</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Rome Criteria for irritable bowel syndrome, fifth revision: Key updates. A review</article-title><trans-title-group xml:lang="ru"><trans-title>Римские критерии синдрома раздраженного кишечника V пересмотра: что нового?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4491-881X</contrib-id><name-alternatives><name xml:lang="en"><surname>Topchii</surname><given-names>Tatiana B.</given-names></name><name xml:lang="ru"><surname>Топчий</surname><given-names>Татьяна Борисовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Assoc. Prof.</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доц., доц. каф. гастроэнтерологии </p></bio><email>tantop@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8150-307X</contrib-id><name-alternatives><name xml:lang="en"><surname>Ardatskaya</surname><given-names>Maria D.</given-names></name><name xml:lang="ru"><surname>Ардатская</surname><given-names>Мария Дмитриевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., проф. каф. гастроэнтерологии </p></bio><email>tantop@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5111-8127</contrib-id><name-alternatives><name xml:lang="en"><surname>Maslovskii</surname><given-names>Leonid V.</given-names></name><name xml:lang="ru"><surname>Масловский</surname><given-names>Леонид Витальевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, доц. каф. гастроэнтерологии</p></bio><email>tantop@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7723-7992</contrib-id><name-alternatives><name xml:lang="en"><surname>Minushkin</surname><given-names>Oleg N.</given-names></name><name xml:lang="ru"><surname>Минушкин</surname><given-names>Олег Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. каф. гастроэнтерологии, проф. </p></bio><email>tantop@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6210-8955</contrib-id><name-alternatives><name xml:lang="en"><surname>Zverkov</surname><given-names>Igor V.</given-names></name><name xml:lang="ru"><surname>Зверков</surname><given-names>Игорь Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., проф. каф. гастроэнтерологии </p></bio><email>tantop@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Central State Medical Academy of the President of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской Федерации</institution></aff></aff-alternatives><content-language>ru</content-language><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2026-09-09"><day>09</day><month>09</month><year>2026</year></pub-date><pub-date date-type="collection"><year>2026</year></pub-date><volume>28</volume><issue>8</issue><issue-title xml:lang="en">Outpatient issues</issue-title><issue-title xml:lang="ru">Поликлинические вопросы</issue-title><fpage>662</fpage><lpage>669</lpage><history><date date-type="received" iso-8601-date="2026-09-09"><day>09</day><month>09</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-09-09"><day>09</day><month>09</month><year>2026</year></date></history><pub-history><event event-type="received"><event-desc>Received:<date date-type="received" iso-8601-date="2026-09-09"><day>09</day><month>09</month><year>2026</year></date></event-desc></event><event event-type="accepted"><event-desc>Accepted:<date date-type="accepted" iso-8601-date="2026-09-09"><day>09</day><month>09</month><year>2026</year></date></event-desc></event><event event-type="pub"><event-desc>Published:<pub-date date-type="pub" publication-format="electronic" iso-8601-date="2026-09-09"><day>09</day><month>09</month><year>2026</year></pub-date></event-desc></event></pub-history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/717853">https://consilium.orscience.ru/2075-1753/article/view/717853</self-uri><abstract xml:lang="en"><p>The Rome V Criteria, published in 2026, updates the scientific and clinical understanding of irritable bowel syndrome (IBS). It redefines IBS from a “functional disorder” to a “gut-brain interaction disorder,” emphasizing biological underpinnings. Recognized pathophysiological mechanisms include impaired motility, alterations in the microbiota and its metabolites, immune dysregulation, serotonin modulation, increased intestinal permeability, visceral hypersensitivity, and bile acid malabsorption. The updated criteria define IBS as recurrent abdominal pain and/or discomfort associated with changes in bowel habits, such as constipation, diarrhea, or a mixed pattern, with symptoms present for at least six months prior to diagnosis and persisting during the preceding three months. Notable updates include the reintroduction of “abdominal discomfort,” a reduced pain frequency threshold of at least three days per week, clarification that pain or discomfort should not be constant, and an auxiliary criterion specifying that pain or discomfort should not be exclusively related to menstruation. IBS is now classified into four primary subtypes based on predominant stool patterns, as determined by the Bristol Stool Form Scale: IBS with constipation, IBS with diarrhea, IBS with mixed bowel habits, and IBS with unclassified bowel habits. Diagnosis is based on typical symptoms in the absence of alarm features, and IBS is no longer considered a diagnosis of exclusion. The revised diagnostic algorithm involves sequential clinical assessment, targeted use of a limited set of laboratory and instrumental tests, and explicit criteria for further evaluation. The Rome V Criteria also recommend a stepwise approach to IBS therapy, including lifestyle and dietary modifications, pharmacological management of predominant symptoms, and behavioral interventions targeting brain-gut axis interactions.</p></abstract><trans-abstract xml:lang="ru"><p>Римские критерии V пересмотра, опубликованные в 2026 г., знаменуют важнейший этап в эволюции научных и клинических представлений о синдроме раздраженного кишечника (СРК). Ключевым достижением стал переход от концепции «функционального расстройства» к термину «расстройство взаимодействия кишечник – мозг», что подчеркивает биологическую основу заболевания, патофизиологическими механизмами которого являются нарушение моторики, микробиоты, качественного и количественного состава ее метаболитов, иммунной регуляции, модуляции серотонина, повышение кишечной проницаемости, висцеральная гиперчувствительность и мальабсорбция желчных кислот. В соответствии с новыми критериями СРК определяется как рецидивирующая боль и/или дискомфорт в животе, связанные с изменениями в ритме дефекации (запор, диарея или смешанное состояние запора и диареи), при этом симптомы должны появиться не менее чем за 6 мес до постановки диагноза и присутствовать в течение предшествующих 3 мес. По сравнению с предыдущими диагностическими критериями возвращено понятие «дискомфорт в животе», установлен более низкий порог частоты боли (до не менее 3 дней в неделю), добавлено уточнение, что боль или дискомфорт не должны быть постоянными, введен вспомогательный критерий о том, что боль/дискомфорт не должны быть связаны только с менструацией. СРК также классифицируется на 4 основных подтипа в зависимости от преобладающего характера стула, определяемого по Бристольской шкале оценки формы стула: СРК с запором, СРК с диареей, СРК со смешанным стулом, СРК с неклассифицированным стулом. Диагноз СРК устанавливается на основании характерных симптомов при отсутствии симптомов тревоги, таким образом, СРК перестает быть диагнозом исключения. Согласно новым Римским критериям алгоритм диагностики СРК предусматривает последовательную оценку клинических данных, целенаправленное применение ограниченного набора лабораторных и инструментальных методов, а также четкие критерии для эскалации обследования. В Римских критериях V пересмотра предлагается поэтапный подход к терапии СРК, который включает модификацию образа жизни и питания, медикаментозное воздействие на наиболее беспокоящие симптомы, поведенческую терапию, ориентированную на взаимодействие по оси «мозг – кишечник».</p></trans-abstract><kwd-group xml:lang="en"><kwd>irritable bowel syndrome</kwd><kwd>Rome criteria</kwd><kwd>functional gastrointestinal disorders</kwd><kwd>low-FODMAP diet</kwd><kwd>psyllium</kwd><kwd>butyric acid</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>синдром раздраженного кишечника</kwd><kwd>Римские критерии</kwd><kwd>функциональные желудочно-кишечные расстройства</kwd><kwd>диета low-FODMAP</kwd><kwd>псиллиум</kwd><kwd>масляная кислота</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">ООО «Доктор Фальк Фарма ГмбХ»</institution></institution-wrap><institution-wrap><institution xml:lang="en">Dr. Falk Pharma GmbH</institution></institution-wrap></funding-source></award-group><funding-statement xml:lang="en">The paper was prepared with the financial support of Dr. Falk Pharma GmbH. The sponsor was not involved in the data collection and analysis and the interpretation of results. In preparing the manuscript, the authors maintained the independence of opinion.</funding-statement><funding-statement xml:lang="ru">Материал подготовлен при финансовой поддержке ООО «Доктор Фальк Фарма ГмбХ». Спонсор не участвовал в сборе, анализе данных, интерпретации результатов. При подготовке рукописи авторы сохранили независимость мнений.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Corsetti M, Shin A, Lacy BE, et al. Bowel Disorders. Gastroenterology. 2026;170(6):1261-82. DOI:10.1053/j.gastro.2026.02.003</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Синдром раздраженного кишечника. Клинические рекомендации Минздрава России. 2024. Режим доступа: https:// cr.minzdrav.gov.ru/view-cr/892_1. Ссылка активна на 20.05.2026 [Sindrom razdrazhennogo kishechnika. Klinicheskie rekomendatsii Minzdrava Rossii. 2024. Available at: https:// cr.minzdrav.gov.ru/view-cr/892_1. Accessed: 20.05.2026 (in Russian)].</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Rubio-Tapia A, Hill ID, Semrad C, et al. American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. Am J Gastroenterol. 2023;118(1):59-76. DOI:10.14309/ajg.0000000000002075</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Bourli P, Eslahi AV, Tzoraki O, Karanis P. Waterborne transmission of protozoan parasites: a review of worldwide outbreaks – an update 2017–2022. J Water Health. 2023;21(10):1421-47. DOI:10.2166/wh.2023.094</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Waseem MR, Shin A, Siwiec R, et al. Associations of Fecal Short Chain Fatty Acids With Colonic Transit, Fecal Bile Acid, and Food Intake in Irritable Bowel Syndrome. Clin Transl Gastroenterol. 2023;14(1):e00541. DOI:10.14309/ctg.0000000000000541</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Calderon G, Patel C, Camilleri M, et al. Associations of Habitual Dietary Intake With Fecal Short-Chain Fatty Acids and Bowel Functions in Irritable Bowel Syndrome. J Clin Gastroenterol. 2022;56(3):234-42. DOI:10.1097/MCG.0000000000001521</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Nunan D, Cai T, Gardener AD, et al. Physical activity for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2022;6(6):CD011497. DOI:10.1002/14651858.CD011497.pub2</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367-74. DOI:10.1038/ajg.2014.195</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Gunn D, Abbas Z, Harris HC, et al. Psyllium reduces inulin-induced colonic gas production in IBS: MRI and in vitro fermentation studies. Gut. 2022;71(5):919-27. DOI:10.1136/gutjnl-2021-324784</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Cuffe MS, Staudacher HM, Aziz I, et al. Efficacy of dietary interventions in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2025;10(6):520-36. DOI:10.1016/S2468-1253(25)00054-8</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2020;116(1):17-44. DOI:10.14309/ajg.0000000000001036</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Moayyedi P, Andrews CN, MacQueen G, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol. 2019;2(1):6-29. DOI:10.1093/jcag/gwy071</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Nikolaki MD, Kasti AN, Katsas K, et al. The Low-FODMAP Diet, IBS, and BCFAs: Exploring the Positive, Negative, and Less Desirable Aspects – A Literature Review. Microorganisms. 2023;11(10):2387. DOI:10.3390/microorganisms11102387</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Caban M, Pikus E, Czarnecka-Chrebelska K, et al. Use of Sodium Butyrate and Its Microencapsulated Forms in Intestinal Diseases – Current Clinical Approach. Dig Dis Sci. 2026;71(5):1626-39. DOI:10.1007/s10620-025-09536-4</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Lewandowski K, Kaniewska M, Karłowicz K, et al. The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Prz Gastroenterol. 2022;17(1):28-34. DOI:10.5114/pg.2021.112681</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Scharf MW, Forsgård RA, Prado SBR, et al. Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model. Gut Microbes. 2025;17(1):2545414. DOI:10.1080/19490976.2025.2545414</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>El-Salhy M, Valeur J, Brønstad I, et al. Possible Role of Butyric Acid in Long-Term Symptom Relief in Irritable Bowel Syndrome Patients Following Fecal Microbiota Transplantation. Neurogastroenterol Motil. 2025;37(12):e70115. DOI:10.1111/nmo.70115</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Wong RK, Fang X, Ghoshal UC, et al. Sociocultural Aspects of the Pathophysiology, Clinical Presentation, and Management of Disorders of Gut-Brain Interaction. Gastroenterology. 2026;170(6):1190-204. DOI:10.1053/j.gastro.2026.02.006</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Cristofori F, Calabrese FM, Iacobellis I, et al. Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo-controlled multiomics-based clinical trial. J Pediatr Gastroenterol Nutr. 2025;81(3):551-61. DOI:10.1002/jpn3.70154</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Андреев Д.Н., Кучерявый Ю.А., Черемушкин С.В., Маев И.В. Эффективность включения масляной кислоты в схемы спазмолитической терапии синдрома раздраженного кишечника: метаанализ контролируемых исследований. Consilium Medicum. 2020;22(8):27-31 [Andreev DN, Kucheryavyy YuA, Cheremushkin SV, Maev IV. The effectiveness of adding butyric acid to antispasmodic therapy regimens for irritable bowel syndrome: a meta-analysis of controlled studies. Consilium Medicum. 2020;22(8):27-31 (in Russian)]. DOI:10.26442/20751753.2020.8.200194</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Бутова Е.Н. Оптимизация современной терапии пациентов с синдромом раздраженного кишечника. Лечащий Врач. 2019;7:53-9. EDN:XIQZJF [Butova EN. Optimizatsiia sovremennoi terapii patsientov s sindromom razdrazhennogo kishechnika. Lechashchi Vrach. 2019;7:53-9 (in Russian)].</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol. 2018;113(5):735-45. DOI:10.1038/s41395-018-0026-7</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Lacy BE, Shin AS, Cangemi DJ, et al. Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysis. Ther Adv Gastroenterol. 2026;19:17562848251414831. DOI:10.1177/17562848251414831</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Busam JA, Batta N, Shah ED, et al. The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2026;121(3):745-53. DOI:10.14309/ajg.0000000000003572</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Black CJ, Yuan Y, Selinger CP, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(2):117-31. DOI:10.1016/S2468-1253(19)30324-3</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Ford AC, Wright-Hughes A, Alderson SL, et al. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10414):1773-85. DOI:10.1016/S0140-6736(23)01523-4</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Goodoory VC, Khasawneh M, Black CJ, et al. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Gastroenterology. 2023;165(5):1206-18. DOI:10.1053/j.gastro.2023.07.018</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Lembo A, Pimentel M, Rao SS, et al. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology. 2016;151(6):1113-21. DOI:10.1053/j.gastro.2016.08.003</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Decraecker L, De Looze D, Hirsch DP, et al. Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial. Gut. 2024;73(3):459-69. DOI:10.1136/gutjnl-2023-331634</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Goodoory VC, Tuteja AK, Black CJ, Ford AC. Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2024;22(2):243-251.e5. DOI:10.1016/j.cgh.2023.02.014</mixed-citation></ref></ref-list></back></article>
